Cargando…

Response to Crudele et al. Commentary on Mayock et al. “In Vitro Drug Release after Crushing: Evaluation of Xtampza(®) ER and Other ER Opioid Formulations”

Detalles Bibliográficos
Autores principales:	Fleming, Alison B., Mayock, Stephen P., Saim, Said
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2018
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6061363/ https://www.ncbi.nlm.nih.gov/pubmed/29949104 http://dx.doi.org/10.1007/s40261-018-0664-y

Ejemplares similares

In Vitro Drug Release After Crushing: Evaluation of Xtampza(®) ER and Other ER Opioid Formulations
por: Mayock, Stephen P., et al.
Publicado: (2017)

Comment on Mayock SP, Saim S, Fleming AB. In Vitro Drug Release After Crushing: Evaluation of Xtampza(®) ER and Other ER Opioid Formulations
por: Crudele, Nancy, et al.
Publicado: (2018)

Response to Crudele et al. Commentary on Gudin et al. “Comparing the Effect of Tampering on the Oral Pharmacokinetic Profiles of Two Extended-Release Oxycodone Formulations with Abuse-Deterrent Properties”
por: Gudin, Jeff, et al.
Publicado: (2017)

Oral Human Abuse Potential of Oxycodone DETERx(®) (Xtampza(®) ER)
por: Kopecky, Ernest A., et al.
Publicado: (2016)

Postmarketing Analysis of Misuse, Abuse, and Diversion of Xtampza ER
por: Geoffrey Severtson, Stevan, et al.
Publicado: (2020)

A Cross-Sectional Study of Tampering in Xtampza ER, an Abuse-Deterrent Formulation of an Extended-Release Opioid, in a Treatment Center Population
por: Jewell, Jennifer, et al.
Publicado: (2023)

Correction to: A Cross-Sectional Study of Tampering in Xtampza ER, an Abuse-Deterrent Formulation of an Extended-Release Opioid, in a Treatment Center Population
por: Jewell, Jennifer, et al.
Publicado: (2023)

Commentary on Simon et al
por: Pascoal, Patrícia M.
Publicado: (2022)

Commentary on Simon et al
por: Shindel, Alan W.
Publicado: (2022)

Response to commentary by Skinner et al. on Regression to the Mean (RTM) in Burke et al.
por: Burke, Rachel M, et al.
Publicado: (2015)

Hypothermia plus Erythropoietin for neonatal neuroprotection? Commentary on Fan et al. and Fang et al.
por: Juul, Sandra E.
Publicado: (2013)

Response to the Commentary from Bevelacqua et al.
por: Limoli, Charles L., et al.
Publicado: (2020)

Cryobiopsy Compared with Surgical Lung Biopsy in ILD: Reply to Maldonado et al., Froidure et al., Bendstrup et al., Agarwal et al., Richeldi et al., Rajchgot et al., and Quadrelli et al.
por: Romagnoli, Micaela, et al.
Publicado: (2019)

Non-exclusive exclusion (Commentary on Capello et al.)
por: Rodriguez-Gil, Diego, et al.
Publicado: (2009)

AAV shuffles to the liver: commentary on Lisowski et al.
por: Schaffer, David V
Publicado: (2014)

Pragmatics for infants: commentary on Wenzel et al. (2020)
por: Rubio-Fernandez, Paula, et al.
Publicado: (2021)

Reply by Gattinoni et al. to Hedenstierna et al., to Maley et al., to Fowler et al., to Bhatia and Mohammed, to Bos, to Koumbourlis and Motoyama, and to Haouzi et al.
por: Gattinoni, Luciano, et al.
Publicado: (2020)

A US Retrospective Claims Analysis Comparing Healthcare Costs of Patients Transitioning from Immediate-Release Oxycodone to Two Different Formulations of Extended-Release Oxycodone: Xtampza ER or OxyContin
por: Olatoke, Oluwadara, et al.
Publicado: (2022)

The need for genetically‐informative designs in developmental science: Commentary on Gustavson et al. (2021) and Myers et al. (2021)
por: Taylor, Mark J.
Publicado: (2021)

Reply to Cottin et al., to Johannson et al., to Scholand and Wells, and to Crowley et al.
por: Raghu, Ganesh, et al.
Publicado: (2022)

Response to Sadek et al. and Kotlikoff et al.
por: Andersen, Ditte Caroline, et al.
Publicado: (2014)

Reply to Lescoat et al. and to Khamis et al.
por: Adegunsoye, Ayodeji, et al.
Publicado: (2019)

Reply to Chase et al. and to Milner et al.
por: Mittel, Aaron M., et al.
Publicado: (2020)

Reply by Xu et al. to Haouzi et al.
por: Xu, Yonghao, et al.
Publicado: (2020)

Reply by Pan et al. to Haouzi et al.
por: Pan, Chun, et al.
Publicado: (2020)

Reply to Topeli et al. and to Akinosoglou et al.
por: Azevedo, Luciano C. P., et al.
Publicado: (2020)

Response to Gould et al. and Vincelli et al.
Publicado: (2017)

Reply to Turnbull et al. and to Hulme et al.
por: Breuer, Oded, et al.
Publicado: (2020)

Reply to Shoemark et al. and to Shapiro et al.
por: Amirav, Israel, et al.
Publicado: (2020)

Reply to Gueret et al. and to Hammond et al.
por: Brown, Ryan M., et al.
Publicado: (2020)

Reply to Blot et al. and to Inoue et al.
por: McElvaney, Oliver J., et al.
Publicado: (2021)

Reply to Sanfilippo et al. and to Caviedes et al.
por: Arachchillage, Deepa J., et al.
Publicado: (2021)

Reply to Jin et al. and to Sun et al.
por: Boucly, Athénaïs, et al.
Publicado: (2021)

Reply to Nie et al. and Bhammar et al.
por: Peters, Michael C., et al.
Publicado: (2022)

Reply to Fillatre et al. and Li et al.
por: Abdul-Aziz, Mohd H., et al.
Publicado: (2022)

Commentary on Lo‐Ciganic et al.: The importance of evidence‐based clinical and policy approaches to reduce opioid harms
por: Samples, Hillary
Publicado: (2022)

CREB signalling in bipolar disease (Commentary on Gaspar et al.)
por: Jagannath, Aarti, et al.
Publicado: (2014)

Commentary: A Comment on Qi et al.—Authors’ Reply
por: Qi, X. Sharon, et al.
Publicado: (2012)

The costs and benefits of diagnosis of ADHD: commentary on Holden et al.
por: Russell, Ginny, et al.
Publicado: (2014)

Deviations from Expectations: A Commentary on Aliev et al.
por: van der Sluis, Sophie, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_emsdcq7uvh2krooi8t3e0ljn6u